Gritstone bio, Inc. financial data

Symbol
GRTS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5959 Horton Street, Suite 300, Emeryville, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Gritstone Oncology, Inc. (to 4/23/2021)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 289 % -46.3%
Debt-to-equity 298 % +419%
Return On Equity -329 % -251%
Return On Assets -82.5 % -38.9%
Operating Margin -934 % +17.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 118M shares +26.9%
Common Stock, Shares, Outstanding 118M shares +29.1%
Entity Public Float 174M USD +1.17%
Common Stock, Value, Issued 24K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 143M shares +24.7%
Weighted Average Number of Shares Outstanding, Diluted 143M shares +24.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 14.6M USD +25.1%
Research and Development Expense 120M USD +1.89%
General and Administrative Expense 31.5M USD +18.1%
Operating Income (Loss) -136M USD -3.12%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -133M USD -1.95%
Earnings Per Share, Basic -1.09 USD/shares +12.8%
Earnings Per Share, Diluted -1.09 USD/shares +12.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 50.9M USD +22.9%
Marketable Securities, Current 4.81M USD -93.4%
Other Assets, Current 467K USD -35%
Assets, Current 60.7M USD -50.4%
Property, Plant and Equipment, Net 12.5M USD -38.7%
Operating Lease, Right-of-Use Asset 64M USD -11.1%
Assets 143M USD -36%
Accounts Payable, Current 4.13M USD -16.1%
Employee-related Liabilities, Current 5.27M USD -12.7%
Accrued Liabilities, Current 856K USD -41%
Contract with Customer, Liability, Current 698K USD -75.2%
Liabilities, Current 23.9M USD +8.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 54.8M USD -9.86%
Other Liabilities, Noncurrent 1.12M USD +181%
Liabilities 120M USD +6.45%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3K USD +97.6%
Retained Earnings (Accumulated Deficit) -723M USD -22.5%
Stockholders' Equity Attributable to Parent 22.2M USD -79.7%
Liabilities and Equity 143M USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.6M USD +16.3%
Net Cash Provided by (Used in) Financing Activities -379K USD -104%
Net Cash Provided by (Used in) Investing Activities 12.3M USD -41.9%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 118M shares +29.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.6M USD -111%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.9M USD +15.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 858K USD +96.8%
Deferred Tax Assets, Valuation Allowance 189M USD +17.3%
Deferred Tax Assets, Gross 206M USD +24%
Operating Lease, Liability 62M USD -5.6%
Payments to Acquire Property, Plant, and Equipment 143K USD -90.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -133M USD -2.08%
Lessee, Operating Lease, Liability, to be Paid 91.2M USD -8.75%
Property, Plant and Equipment, Gross 47.5M USD -7.45%
Operating Lease, Liability, Current 7.16M USD +48%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.4M USD -2.98%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.4M USD -9.63%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.2M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.5M USD +0.51%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +3.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 14.9M USD +121%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.7M USD +2.17%
Operating Lease, Payments 3.14M USD +50.1%
Additional Paid in Capital 746M USD +6.51%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 17M USD +238%
Share-based Payment Arrangement, Expense 12.5M USD +5.02%
Interest Expense 4.81M USD +58.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%